165 related articles for article (PubMed ID: 30538442)
1. Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD.
Dong W; Du Y; Ma S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3805-3812. PubMed ID: 30538442
[TBL] [Abstract][Full Text] [Related]
2. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.
Omote N; Hashimoto N; Morise M; Sakamoto K; Miyazaki S; Ando A; Nakahara Y; Hasegawa Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3541-3547. PubMed ID: 29270008
[TBL] [Abstract][Full Text] [Related]
3. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
Dong W; Zhu Y; Du Y; Wang L; Feng X; Ma S
Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
[TBL] [Abstract][Full Text] [Related]
4. Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors.
Izquierdo JL; Resano P; El Hachem A; Graziani D; Almonacid C; Sánchez IM
Int J Chron Obstruct Pulmon Dis; 2014; 9():1053-8. PubMed ID: 25336937
[TBL] [Abstract][Full Text] [Related]
5. Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
Dong W; Yin Y; Yang S; Liu B; Chen X; Wang L; Su Y; Jiang Y; Shi D; Sun D; Qin J
BMC Cancer; 2024 Jan; 24(1):153. PubMed ID: 38291354
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2019; 14():929-938. PubMed ID: 31118602
[No Abstract] [Full Text] [Related]
7. [Impact of Chronic Obstructive Pulmonary Disease on Risk of Recurrence in Patients with Resected Non-small Cell Lung Cancer].
Qiang G; Yu Q; Liang C; Song Z; Shi B; Guo Y; Liu D
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):215-220. PubMed ID: 29587946
[TBL] [Abstract][Full Text] [Related]
8. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.
Volpino P; Cangemi R; Fiori E; Cangemi B; De Cesare A; Corsi N; Di Cello T; Cangemi V
J Cardiovasc Surg (Torino); 2007 Jun; 48(3):375-83. PubMed ID: 17505444
[TBL] [Abstract][Full Text] [Related]
9. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection.
Zhai R; Yu X; Shafer A; Wain JC; Christiani DC
Chest; 2014 Feb; 145(2):346-353. PubMed ID: 24008835
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
11. Long-term surgical outcome in patients with lung cancer and coexisting severe COPD.
Nakajima T; Sekine Y; Yamada Y; Suzuki H; Yasufuku K; Yoshida S; Suzuki M; Shibuya K; Fujisawa T; Yoshino I
Thorac Cardiovasc Surg; 2009 Sep; 57(6):339-42. PubMed ID: 19707975
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision.
Qin J; Li G; Zhou J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1515-20. PubMed ID: 27445471
[TBL] [Abstract][Full Text] [Related]
14. Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
Jeppesen SS; Hansen NG; Schytte T; Nielsen M; Hansen O
Lung Cancer; 2016 Oct; 100():90-95. PubMed ID: 27597286
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study.
Makinson A; Tenon JC; Eymard-Duvernay S; Pujol JL; Allavena C; Cuzin L; Poizot-Martin I; de la Tribonnière X; Cabié A; Pugliese P; Reynes J; Le Moing V
J Thorac Oncol; 2011 Jun; 6(6):1022-9. PubMed ID: 21512403
[TBL] [Abstract][Full Text] [Related]
16. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer.
Qiang G; Liang C; Xiao F; Yu Q; Wen H; Song Z; Tian Y; Shi B; Guo Y; Liu D
Int J Chron Obstruct Pulmon Dis; 2016; 11():43-9. PubMed ID: 26766906
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2018; 13():2139-2146. PubMed ID: 30034229
[TBL] [Abstract][Full Text] [Related]
19. Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis.
Tuminello S; Alpert N; Veluswamy RR; Kumar A; Gomez JE; Flores R; Taioli E
BMC Cancer; 2022 Jan; 22(1):80. PubMed ID: 35045806
[TBL] [Abstract][Full Text] [Related]
20. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
